There are 3 Food and Drug Administration (FDA)-approved vaccines currently available and recommended in the US for use in children for the protection against invasive pneumococcal disease.
PCV20 (Prevnar 20, Wyeth/Pfizer)
- FDA approved in 2023
- For children ages 6 weeks and older
- Includes serotypes: serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F
- Recommended for routine immunization in children age 2 – 24 months and for children with risk conditions
- May be administered to children with risk conditions who have previously only received PCV15
PCV15 (Vaxneuvance, Merck)
- FDA approval in 2021
- FDA approval expanded to children ages 6 weeks through 17 years in 2022, followed by CDC Advisory Committee on Immunization Practices recommendation for routine immunization in children age 2 – 23 months and for children age 6 – 18 years with risk conditions, who have not yet been vaccinated with PCV13, PCV15, or PCV20.
- Includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.
- Children with risk conditions who have only received PCV15 may need at least one dose of PCV20 or PPSV23
PPSV23 (Pneumovax, Merck)
- FDA Approved in 1983
- Includes serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
- Recommended for children ages 24 months and older who are at increased risk of pneumococcal disease
- May be administered to children with risk conditions who have previously only received PCV15
Last Updated
01/08/2024
Source
American Academy of Pediatrics